Subject index of Volume 137 · 1998

Acquisition 81, 132
ACTH 247, 351
Active avoidance test 369
Activity 99
Adenosine A_2 receptor 113
Alcohol 25, 215
Alcoholism 311
Allopregnanolone 391
Alternative reinforcer 132
Amisulpride 223
Amphetamine 33, 410
Anandamide 147
Anorectic agents 99
Antipsychotic 61
Antipsychotic efficacy 223
Anxiety 120, 333, 351
Anxiety disorder 311
AP-5 175
Appetite 391
Associative learning 90
Attention 410
Atypical 61
Atypical antipsychotic 139
Atypical neuroleptic 223
Autoshaping 81
Behavioral sensitization 282
Benzodiazepine 164, 215
Biogenic amine synthesis 74
Blood pressure 233
Caffeine 81, 401
Caged-dopamine 303
Captivity 205
Cardiovascular effects 15
Catalepsy 113, 147
CCK 120
CGP 55845A 369
CGP 62349 369
CGP 71982 369
4′-Chlordiazepam 391
Chlordiazepoxide 215
Chronic haloperidol 107
Cis(*Z*)-flupentixol 215
[^{123}I]β-CIT 321
Classical conditioning 157, 333
Clozapine 341
Cocaine 1, 15, 81, 184, 253, 303, 321
Corticosterone 351
Corticotropin-releasing factor 184
Cortisol 247
Cotinine replacement 345
CRF antagonist 333
CRF receptor 184
Cross-tolerance 67
Cytokine 351
Decerebrate 43
Dehydroepiandrosterone sulfate 391
Dependence 67
3,4-Diaminopyridine 74
Diazepam 215
Dizocilpine (MK-801) 205
Dopamine 1, 61, 223, 351
Dopamine transporter 321
Dose 132
Dosing 139
Drug abuse 333
Drug addiction 410
Drug discrimination 1, 164, 233, 292
Drug self-administration 132, 184
Drugs of abuse 7
DTG 191
Dynorphin 326
Dyskinesia 191
Efficacy 139
Ejaculation 374
Elevated plus-maze 333
Endogenous dopamine 303
Environment 90
EPS 139
Ethanol 25
Ethanol withdrawal 120
Expired carbon monoxide 345
Exploration 351
Extrapyramidal tolerability 223
Facial nucleus 191
Family history 311
Feeding 43
Fentanyl 67
Flavour-conditioning 401
Flumazenil 215
Flupentixol 223
Food deprivation 81
Fos 282
Fourth ventricle 43
GABA 247
GABA-A receptor 391
$GABA_B$ receptor antagonist 369
Gabapentin 74
Gating 362
Gender 311, 362
Glucose 259
Granulocytopenia 341
Growth hormone 247
Habituation 175, 241
Haloperidol 50, 191
Heart rate 233
Heroin 184
5-HT 43, 113
5-HT receptor 113, 374
5-HT_{1A} receptor 1, 25
5-HT_{2A} receptor 25
5-HT_{2C} 292
5-HTP 374
Human 15, 326, 362
8-Hydroxy-2-(di-*N*-propylamino) tetralin (DPAT) 1
Hypothermia 233
Individual differences 205
Intravenous self-administration 81
Kappa opioid 282
Ketamine 271
Learning and memory 369
Lick force 50
Lick rhythm 50
Licking 50
Locomotion 205, 233, 241
Locomotor activity 175, 282
Long-term memory 259
LY-53,857 157
Male rat 374
Matching to position 7
Mazindol 321
mCPP (*m*-chlorophenylpiperazine) 292
MDL-11,939 157
Medication development 321
Melatonin 247
Memory 7, 241
Mesulergine 43
Metabolism 341
Mg^{2+} 247
Microinjection 1
Midazolam 215
Mirfentanil 67
Mitochondrial DBI receptor 391
Mixed D_1-/D_2-like antagonism 223
Mixture analysis 107
MK-801 175, 241
Mood 401
Morphine 67
Motor 147
Motor performance 157
Movement 33
Movement disorders 191
Muscarinic receptors 233
NECA 113
Negative reinforcement 401
Neuroleptics 50
Neurosteroids 391
Nicotine 362
Nicotine metabolism 383
Nicotine nasal spray 345
Nicotine replacement 345
Nictitating membrane 157
NMDA 241, 247, 271
NMDA receptor 205, 391
Non-opioid 67
Non-verbal memory 259
Norepinephrine 351
Norepinephrine release 74
Nucleus accumbens 175, 303
Object novelty 175
OHM3295 67
OHM3463 67
Ontogeny 282
Open-field 241
Operant 61
Opiate withdrawal 326
Opioid 67, 164
Oral phencyclidine 132
P50 reduction 271
Palatability 215
Parkinsonism 50, 61
PCP 132
Performance 15
Pergolide 15
Plasma nicotine 383
Plus maze 120
Pregnenolone sulfate 391
Prepulse inhibition 271, 362
Progesterone 391
Prolactin 247
Psychosis 410
Quetiapine 139
Quipazine 50
Rabbit 157
Raclopride 33
Rat 25, 90, 292
Rat brain regions 74
Rats 7, 81, 107
Reaction time 33
Reinstatement 184
Relapse 184
Response initiation 147
Reward 215
Rhesus monkey 33, 253

Rhesus monkeys 132, 164
Ritanserin 50, 157
Rodents 233
Rotational behavior 90
Saccharin 25, 81, 132, 259
Salivation 233
SCH 39166 33
Schizophrenia 139, 223, 271
Scopolamine 50
Selective D_2-like antagonism 223
Self-administration 15, 25, 253
Sensitization 410
Serotonin 1, 25, 99, 113, 351
Serotonin 5-$HT_{2A/2C}$ receptor 157
Sex differences 15
Sexual behavior 374
Short-term memory 259
Sigma receptors 191
Sleep 247
Sleep EEG 247
Sleep spindles 247
Smoking 362
Smoking cessation 345
Sniffing 205
Spatial alternation 7
Spatial novelty 175
Spinal trigeminal nucleus 191
Spontaneous alternation 351
Startle 362
Stereotyped behaviour 205
Stress 90, 184, 311, 383
Subjective effects 15
Substitution therapy 253
Tardive dyskinesia 50, 107
Taste 215
Tetrahydrocannabinol 147
TFMPP 99
THC 147
Tolerability 139
Tolerance 67
Tongue 50
Tremor 61, 233
Trihexyphenidyl 50
U-50,488 282
Uptake inhibition 303
Vacuous chewing 61
Vacuous chewing movements 107
Ventilation 164
Ventral tegmental area 1
Verbal memory 259
Voltammetry 303
Water intake 99
WAY 100635 1
Withdrawal 401
Young control participants 259